It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Starting your investment journey? Learn what to watch out for as a new investor to avoid common pitfalls and make wise choices.
27,695 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Quantum computing is still in its early innings, and Rigetti Computing sits at a pivotal crossroads. This article bre...
The S&P 500 dropped around 1.5% as crude surged on geopolitical worries, reviving inflation fears and tempering expec...
A JPMorgan analyst forecasts looming oil shortages within weeks, drawing a sharp response from investors and fund man...
As 2026 unfolds, investors debate what’s best crypto between XRP, Solana and BNB, weighing use cases, network upgrade...
Chipmakers led a broad rebound as the S&P 500 climbed on June 8, 2026. The session showed tech rotation returning to ...
A Florida couple filed suit against Compass over a $475 closing fee, arguing the charge was undisclosed and improper,...
Rivian priced a 75 million share secondary offering, sending its stock down around 14% and triggering a market-wide p...
VanEck's NLR ETF blends uranium miners, enrichers and reactor operators, trading at 0.61%, as investors seek a balanc...
Bitcoin holds near $66,000 as geopolitical shocks test the rebound. A UN Security Council warning and Hormuz oil fear...
A prominent chart analyst points to a long-term XRP pattern suggesting a dramatic upside in the next market cycle. Tr...
Alibaba's Qwen AI released a structured forecast for Bitcoin, Ethereum, and XRP by end-May 2026, tying targets to ETF...